President, Chief Medical Officer and Executive Chair · SpyGlass Pharma, Inc. (SGP)

Malik Kahook

A named executive officer of SpyGlass Pharma in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$2,484,469

Salary $0Stock awards $0

FY2024: $379,454

2nd of 3 named executive officers at SpyGlass Pharma by FY2025 total.

3 named officers on file for SpyGlass Pharma, FY2025

Malik Kahook’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how SpyGlass Pharma’s whole pay program stands against its peers

  • SpyGlass Pharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SGP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 26, 2026 (10-K).

Free

Get Malik Kahook’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Malik Kahook compensation by year

SpyGlass Pharma Summary Compensation Table · all 2 fiscal years held
In US dollars, as SpyGlass Pharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$0$0
Bonus$0$0
Stock awards$0$0
Option awards$0$2,060,244
Non-equity incentive$91,287$125,975
Pension and deferred compensation$0$0
All other$288,167$298,250
Total$379,454$2,484,469

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SpyGlass Pharma, Inc. 10-K filed March 26, 2026, accession 0001778922-26-000020, and prior-year filings. Open the filing on EDGAR.

How this page was built: the SpyGlass Pharma, Inc. filed document, accession 0001778922-26-000020. Every figure is read from that document and cited to the page and table it appears in. Filed March 26, 2026.

$379K
$2.5M
FY24
FY25
Non-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option191,874—$2.87
Option33,179—$2.18
Option170,475—$7.11

Per the Outstanding Equity Awards at Fiscal Year-End table in SpyGlass Pharma, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

SpyGlass Pharma’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Patrick MooneyChief Executive Officer$3,322,711
Malik Kahook · this pagePresident, Chief Medical Officer and Executive Chair$2,484,469
Chetan PujaraChief Research & Development Officer$1,539,952

The full SpyGlass Pharma compensation record

free company brief

This page is one person within SpyGlass Pharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SpyGlass Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Malik Kahook's compensation dossier · One-time report. No refunds.